Fifteen years ago, a structural analysis of the hormone insulin and the retinoblastoma tumor suppressor protein (RB) revealed that they may physically interact with one another. Subsequently, an RB peptide corresponding to the proposed RB binding site for insulin was found to recognize full-length insulin in vitro. As part of efforts aimed at developing this RB peptide into an anti-cancer drug, this molecule was chemically coupled properties, yet to a much lesser extent by a control peptide. Thus, this investigation has yielded another important proof for the occurrence of the insulin-RB dimer and, furthermore, its validity as a target for antineoplastic MCR peptides.
INTRODUCTION
Over the past two decades, it has become clear that the healthy state of tissues is maintained by the functional balance between growth-promoting factors and tumor suppressor proteins. Among the latter, retinoblastoma protein (RB) plays a prominent role and, therefore, appears suitable to serve as a template for the design of anti-cancer drugs.
In this context, MCR peptides have been developed to replace defective RB and thereby to even surpass its normal counterpart. Their active site is an RB fragment recognizing the hormone and growth factor insulin (1, 2) . MCR peptides have been shown to inhibit human cancer cell proliferation in vitro (3, 4) and in vivo (5,6).
As previously shown in an immunofluorescence study for MCR-10, i.e. one of the members of the MCR peptide family (4) , this type of compounds appears to achieve this effect, at least in part, by disrupting the physical interaction between insulin and RB, thus preventing that RB is inactivated by insulin. Since such interaction has also been demonstrated by sequential co-immunoprecipitation and immunoblotting (7), we have now chosen a magnetic beads-based variation of this approach to further investigate both the existence of the insulin-RB heterodimer and its possible disruption by two distinct MCR peptides as compared to a control peptide. The disruption of the insulin-RB complex was equally observed when MCR-10 was used (Fig. 3, lane 2) . In this experiment, MCR-16 has hardly influenced the occurrence of insulin-RB dimer formation and thus could not prevent the apparition of a clearcut RB band (Fig. 3, lane 3) .
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As an additional control to those cells not treated with any peptide, yet subjected to the procedure of co-immunoprecipitation with the antibody to insulin and subsequent immunoblotting with the antibody to RB (Fig. 3, lane 1) as well as other cells directly subjected to RB immunoblotting without prior insulin co-immunoprecipitation (Fig. 3 , lane 5), we also included a condition (Fig. 3, lane 4) in which the antibody to insulin had been left out from the combined immunoprecipitation/RB immunoblot procedure to check for the presence of any non-specific matrix/magnetic bead effects. This type of RB immunoblot yielded no visible band (Fig. 3 , lane 4) which upon densitometric analysis corresponded to an only minimal signal (data not shown).
DISCUSSION
The purpose of the present study has been to investigate if the range of cells in which one can observe insulin-RB complexes can be extended from human HepG2 hepatoma cells Thirdly, towards attempting to minimize the development of any potential cancer cell resistance to therapy, it should be specified that, based on the results of this study,
MCR-4 appears to have at least two distinct mechanisms of action and should therefore be a particularly suitable drug candidate. As such, MCR-4 not only interferes with the physical interaction between insulin and RB, as demonstrated here, but has also been shown to induce a high intracellular level of the cyclin-dependent kinase (cdk) inhibitor p21 in A549 cells that was found to coincide with their rapid apoptosis (13) . Since this cell death occurred in the absence of any apparent caspase activation, this MCR-4 mechanism is thus devoid of yet another potential cause for drug resistance.
Taken together, our present data support the notion of a potential involvement of the insulin-RB complex in cancer pathophysiology and, moreover, warrant further accelerated development of MCR peptides, in particular of MCR-4, into clinically applicable anti-cancer drugs.
